How effective is tepotinib in treating lung cancer? Clinical data and survival

Tepotinib is an oral small molecule kinase inhibitor specifically designed for the targeted treatment of patients with MET exon 14 skipping mutation (METex14 skipping mutation) non-small cell lung cancer (NSCLC) . This mutation is a driver gene mutation that causes cancer cells to evade recognition by the immune system and continue to proliferate. Tepotinib effectively inhibits tumor growth by highly selectively inhibiting abnormal signal transduction of the MET pathway and has become an important type of personalized treatment drug. Its approval for marketing marks the further expansion of precision medicine in the field of lung cancer treatment, especially providing new hope for patients for whom traditional treatment options are ineffective.

In key clinical studies completed abroad (such asVISION trial), tepotinib has shown good response rates and disease control rates in treated patients. Although specific percentage data are not quoted here due to SEO strategies, it can be clearly stated that the drug provides a significant objective response to patients with advanced NSCLC carrying MET mutations. Some patients' tumors have significantly shrunk on imaging, and they have even shown a certain efficacy in the case of brain metastasis. At the same time, it has a relatively small impact on patients’ quality of life and can be used as an important option for first-line or later-line treatment.

As for survival, although individual differences are significant, studies have shown that most patients can extend their progression-free survival after receiving tepotinib treatment, and in some cases maintain remission for several months to more than a year. Especially in patients who have not received other targeted or immunotherapies, the efficacy is more durable. It should be emphasized that the efficacy is closely related to the patient's genetic background, previous treatment history, disease stage and other factors. It is recommended to conduct comprehensive molecular testing before receiving treatment to evaluate adaptability and expected efficacy.

Reference materials:https://www.tepotinib.com/